Giovanna Zoccoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giovanna Zoccoli has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
Chiara Berteotti
University of Bologna
32 shared publications- Stefano Bastianini
PRISM Lab, Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
30 shared publications Alessandro Silvani
PRISM Lab, Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy
28 shared publications- Viviana Lo Martire
PRISM Lab, Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
22 shared publications Carlo Franzini
Dipartimento di Fisiologia Umana e Generale, Alma Mater Studiorum - Università di Bologna, Bologna, Italy
20 shared publications- Alessandro Silvani
Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy
19 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Microwaves
- Vol. 6 (2) , 561-573
Wireless Power Transfer-Enabled Optogenetic Stimulation of Hypoglossal Motoneurons in Mice for Functional Studies in Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a widespread sleep-related breathing disorder linked to cardiovascular and cognitive complications. Although continuous positive airway pressure (CPAP) remains the standard therapy, poor patient adherence limits its effectiveness. Hypoglossal nerve stimulation is a promising alternative, and optogenetic activation offers superior spatiotemporal precision. However, before clinical use, this approach requires thorough validation in animal models using platforms that preserve natural behavior. This work proposes a fully wireless alternative to conventional optogenetic platforms which rely on tethered optical fibers, restricting the animal's mobility, inducing tissue inflammation, and limiting experimental flexibility. Fully implantable, miniaturized systems with wireless power transfer (WPT) and control capabilities address the need for reduced invasiveness, enabling natural behavior and long-term studies. We present the design and the in vivo validation of a battery-free, wireless optogenetic platform for in vivo studies on small laboratory mice, designed to minimize device size, weight, and invasiveness. A conformal WPT system of inductive resonant transmitting coils at 13.56 MHz is proposed to be integrated into the laboratory cage hosting the mice. A miniaturized, lightweight, and flexible receiving system (weighing less than 0.6 g) is designed to be implanted on the back of the mouse in a saddle-like configuration. The implanted device hosts the rectification circuitry, used to drive a microscale light-emitting diode (LED) positioned over the hypoglossal nuclei. In this way, optogenetic stimulation without fiber-optic tethers is obtained. Full-wave electromagnetic simulations and experimental validation are first carried out to assess the WPT link performance, demonstrating high tolerance to relative translational and angular displacement between the transmitting and receiving coils, and stable harvested power across the cage volume. For a transmitted power of 1.5 W, a minimum DC power of 20 mW has been obtained in the worst-case position of the mouse inside the cage, sufficient for the LED operation. Finally, in vivo experiments are presented, confirming not only the LED activation but also the hypoglossal nerve stimulation, fully compliant with the radiant flux requirements for optogenetic neurostimulation under realistic conditions. These results demonstrate the feasibility and robustness of the proposed WPT system for untethered, battery-free optogenetic stimulation in lightweight murine models with OSA, providing a platform for preclinical neuroscience research, paving the way toward next-generation low-invasiveness neuromodulation strategies.
- 1 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Microwaves
- Vol. 6 (2) , 561-573
Open AccessWireless Power Transfer-Enabled Optogenetic Stimulation of Hypoglossal Motoneurons in Mice for Functional Studies in Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a widespread sleep-related breathing disorder linked to cardiovascular and cognitive complications. Although continuous positive airway pressure (CPAP) remains the standard therapy, poor patient adherence limits its effectiveness. Hypoglossal nerve stimulation is a promising alternative, and optogenetic activation offers superior spatiotemporal precision. However, before clinical use, this approach requires thorough validation in animal models using platforms that preserve natural behavior. This work proposes a fully wireless alternative to conventional optogenetic platforms which rely on tethered optical fibers, restricting the animal's mobility, inducing tissue inflammation, and limiting experimental flexibility. Fully implantable, miniaturized systems with wireless power transfer (WPT) and control capabilities address the need for reduced invasiveness, enabling natural behavior and long-term studies. We present the design and the in vivo validation of a battery-free, wireless optogenetic platform for in vivo studies on small laboratory mice, designed to minimize device size, weight, and invasiveness. A conformal WPT system of inductive resonant transmitting coils at 13.56 MHz is proposed to be integrated into the laboratory cage hosting the mice. A miniaturized, lightweight, and flexible receiving system (weighing less than 0.6 g) is designed to be implanted on the back of the mouse in a saddle-like configuration. The implanted device hosts the rectification circuitry, used to drive a microscale light-emitting diode (LED) positioned over the hypoglossal nuclei. In this way, optogenetic stimulation without fiber-optic tethers is obtained. Full-wave electromagnetic simulations and experimental validation are first carried out to assess the WPT link performance, demonstrating high tolerance to relative translational and angular displacement between the transmitting and receiving coils, and stable harvested power across the cage volume. For a transmitted power of 1.5 W, a minimum DC power of 20 mW has been obtained in the worst-case position of the mouse inside the cage, sufficient for the LED operation. Finally, in vivo experiments are presented, confirming not only the LED activation but also the hypoglossal nerve stimulation, fully compliant with the radiant flux requirements for optogenetic neurostimulation under realistic conditions. These results demonstrate the feasibility and robustness of the proposed WPT system for untethered, battery-free optogenetic stimulation in lightweight murine models with OSA, providing a platform for preclinical neuroscience research, paving the way toward next-generation low-invasiveness neuromodulation strategies.
- Open Access
- 10 April 2025
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 6 (2) , zpaf025
Probability estimation of narcolepsy type 1 in DTA mice using unlabeled EEG and EMG data
The manual evaluation of mouse sleep studies is labor-intensive and time-consuming. Although several approaches for automatic sleep stage classification have been proposed, no automatic pipeline for detecting a specific mouse phenotype has yet been developed. Here, we present a fully automated pipeline for estimating the probability of Narcolepsy Type 1 (NT1) in the hypocretin-tTA;TetO-Diphteria toxin A (DTA) mouse model using unlabeled electroencephalographic (EEG) and electromyographic (EMG) data. The pipeline is divided into three modules: (1) automatic sleep stage classification, (2) feature extraction, and (3) phenotype classification. We trained two automatic sleep stage classifiers, UsleepEEG and UsleepEMG, using data from 83 wild-type (WT) mice. We next computed features such as EEG spectral power bands, EMG root mean square, and bout metrics from 11 WT and 19 DTA mice. The features were used to train an L1-penalized logistic regression classifier in a Leave-One-Subject-Out approach, achieving an accuracy of 97%. Finally, we validated the pipeline in a held-out dataset of EEG/EMG recordings at four different timepoints during disease development in seven DTA mice, finding that the pipeline captured disease progression in all mice. While our pipeline generalizes well to data from other laboratories, it is sensitive to artifacts, which should be considered in its application. With this study, we present a pipeline that facilitates a fast assessment of NT1 probability in the DTA model and thus can accelerate large-scale evaluations of NT1 treatments.
- 10 April 2025
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 6 (2) , zpaf025
Open AccessProbability estimation of narcolepsy type 1 in DTA mice using unlabeled EEG and EMG data
The manual evaluation of mouse sleep studies is labor-intensive and time-consuming. Although several approaches for automatic sleep stage classification have been proposed, no automatic pipeline for detecting a specific mouse phenotype has yet been developed. Here, we present a fully automated pipeline for estimating the probability of Narcolepsy Type 1 (NT1) in the hypocretin-tTA;TetO-Diphteria toxin A (DTA) mouse model using unlabeled electroencephalographic (EEG) and electromyographic (EMG) data. The pipeline is divided into three modules: (1) automatic sleep stage classification, (2) feature extraction, and (3) phenotype classification. We trained two automatic sleep stage classifiers, UsleepEEG and UsleepEMG, using data from 83 wild-type (WT) mice. We next computed features such as EEG spectral power bands, EMG root mean square, and bout metrics from 11 WT and 19 DTA mice. The features were used to train an L1-penalized logistic regression classifier in a Leave-One-Subject-Out approach, achieving an accuracy of 97%. Finally, we validated the pipeline in a held-out dataset of EEG/EMG recordings at four different timepoints during disease development in seven DTA mice, finding that the pipeline captured disease progression in all mice. While our pipeline generalizes well to data from other laboratories, it is sensitive to artifacts, which should be considered in its application. With this study, we present a pipeline that facilitates a fast assessment of NT1 probability in the DTA model and thus can accelerate large-scale evaluations of NT1 treatments.
- Open Access
- 24 July 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (2) , e14295
Characterisation of sleep apneas and respiratory circuitry in mice lacking CDKL5
Summary: CDKL5 deficiency disorder is a rare genetic disease caused by mutations in the CDKL5 gene. Central apneas during wakefulness have been reported in patients with CDKL5 deficiency disorder. Studies on CDKL5‐knockout mice, a CDKL5 deficiency disorder model, reported sleep apneas, but it is still unclear whether these events are central (central sleep apnea) or obstructive (obstructive sleep apnea) and may be related to alterations of brain circuits that modulate breathing rhythm. This study aimed to discriminate central sleep apnea and obstructive sleep apnea in CDKL5‐knockout mice, and explore changes in the somatostatin neurons expressing high levels of neurokinin‐1 receptors within the preBötzinger complex. Ten adult male wild‐type and 12 CDKL5‐knockout mice underwent electrode implantation for sleep stage discrimination and diaphragmatic activity recording, and were studied using whole‐body plethysmography for 7 hr during the light (resting) period. Sleep apneas were categorised as central sleep apnea or obstructive sleep apnea based on the recorded signals. The number of somatostatin neurons in the preBötzinger complex and their neurokinin‐1 receptors expression were assessed through immunohistochemistry in a sub‐group of animals. CDKL5‐knockout mice exhibited a higher apnea occurrence rate and a greater prevalence of obstructive sleep apnea during rapid eye movement sleep, compared with wild‐type, whereas no significant difference was observed for central sleep apnea. Moreover, CDKL5‐knockout mice showed a reduced number of somatostatin neurons in the preBötzinger complex, and these neurons expressed a lower level of neurokinin‐1 receptors compared with wild‐type controls. These findings underscore the pivotal role of CDKL5 in regulating normal breathing, suggesting its potential involvement in shaping preBötzinger complex neural circuitry and controlling respiratory muscles during sleep.
- 24 July 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (2) , e14295
Open AccessCharacterisation of sleep apneas and respiratory circuitry in mice lacking CDKL5
Summary: CDKL5 deficiency disorder is a rare genetic disease caused by mutations in the CDKL5 gene. Central apneas during wakefulness have been reported in patients with CDKL5 deficiency disorder. Studies on CDKL5‐knockout mice, a CDKL5 deficiency disorder model, reported sleep apneas, but it is still unclear whether these events are central (central sleep apnea) or obstructive (obstructive sleep apnea) and may be related to alterations of brain circuits that modulate breathing rhythm. This study aimed to discriminate central sleep apnea and obstructive sleep apnea in CDKL5‐knockout mice, and explore changes in the somatostatin neurons expressing high levels of neurokinin‐1 receptors within the preBötzinger complex. Ten adult male wild‐type and 12 CDKL5‐knockout mice underwent electrode implantation for sleep stage discrimination and diaphragmatic activity recording, and were studied using whole‐body plethysmography for 7 hr during the light (resting) period. Sleep apneas were categorised as central sleep apnea or obstructive sleep apnea based on the recorded signals. The number of somatostatin neurons in the preBötzinger complex and their neurokinin‐1 receptors expression were assessed through immunohistochemistry in a sub‐group of animals. CDKL5‐knockout mice exhibited a higher apnea occurrence rate and a greater prevalence of obstructive sleep apnea during rapid eye movement sleep, compared with wild‐type, whereas no significant difference was observed for central sleep apnea. Moreover, CDKL5‐knockout mice showed a reduced number of somatostatin neurons in the preBötzinger complex, and these neurons expressed a lower level of neurokinin‐1 receptors compared with wild‐type controls. These findings underscore the pivotal role of CDKL5 in regulating normal breathing, suggesting its potential involvement in shaping preBötzinger complex neural circuitry and controlling respiratory muscles during sleep.
- Open Access
- 20 July 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (2) , e14287
Ageing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice
Summary: Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at different ages. Four groups of age‐matched female KO and WT mice (16 weeks of age: 8 KO‐YO and 9 WT‐YO mice; 87 weeks of age: 13 KO‐OLD and 12 WT‐OLD mice) were implanted with electrodes for discriminating wakefulness, rapid‐eye‐movement sleep (REMS), and non‐REMS (NREMS). Mice were recorded for 48 h in their home cages and for 7 more hours into a plethysmographic chamber to characterise their sleep‐breathing pattern. Regardless of orexin deficiency, OLD mice spent less time awake and had fragmentation of this behavioural state showing more bouts of shorter length than YO mice. OLD mice also had more NREMS bouts and less frequent NREMS apneas than YO mice. Regardless of age, KO mice showed cataplexy‐like episodes and shorter REMS latency than WT controls and had a faster breathing rate and an increased minute ventilation during REMS. KO mice also had more wakefulness, NREMS and REMS bouts, and a shorter mean length of wakefulness bouts than WT controls. Our experiment indicated that the lack of orexins as well as ageing importantly modulate the sleep and breathing phenotype in mice. The narcoleptic phenotype caused by orexin deficiency in female mice was substantially preserved with ageing.
- 20 July 2024
- Published by Wiley in Journal of Sleep Research
- Vol. 34 (2) , e14287
Open AccessAgeing‐related modification of sleep and breathing in orexin‐knockout narcoleptic mice
Summary: Narcolepsy type‐1 (NT1) is a lifelong sleep disease, characterised by impairment of the orexinergic system, with a typical onset during adolescence and young adulthood. Since the wake–sleep cycle physiologically changes with ageing, this study aims to compare sleep patterns between orexin‐knockout (KO) and wild type (WT) control mice at different ages. Four groups of age‐matched female KO and WT mice (16 weeks of age: 8 KO‐YO and 9 WT‐YO mice; 87 weeks of age: 13 KO‐OLD and 12 WT‐OLD mice) were implanted with electrodes for discriminating wakefulness, rapid‐eye‐movement sleep (REMS), and non‐REMS (NREMS). Mice were recorded for 48 h in their home cages and for 7 more hours into a plethysmographic chamber to characterise their sleep‐breathing pattern. Regardless of orexin deficiency, OLD mice spent less time awake and had fragmentation of this behavioural state showing more bouts of shorter length than YO mice. OLD mice also had more NREMS bouts and less frequent NREMS apneas than YO mice. Regardless of age, KO mice showed cataplexy‐like episodes and shorter REMS latency than WT controls and had a faster breathing rate and an increased minute ventilation during REMS. KO mice also had more wakefulness, NREMS and REMS bouts, and a shorter mean length of wakefulness bouts than WT controls. Our experiment indicated that the lack of orexins as well as ageing importantly modulate the sleep and breathing phenotype in mice. The narcoleptic phenotype caused by orexin deficiency in female mice was substantially preserved with ageing.
- Open Access
Increased hippocampal epigenetic age in the Ts65Dn Mouse Model of Down Syndrome
Down syndrome (DS) is a segmental progeroid genetic disorder associated to multi-systemic precocious ageing phenotypes, which are particularly evident at the immune and nervous systems. Accordingly, people with DS show an increased biological age as measured by epigenetic clocks. Ts65Dn trisomic mouse, which harbors extra-numerary copies of Hsa21-syntenic regions, was shown to recapitulate several progeroid features of DS, but no biomarkers of age have been applied to it so far. Here we used a mouse specific epigenetic clock to measure epigenetic age of hippocampi from Ts65Dn and euploid mice at 20 weeks. Ts65Dn mice showed an increased hippocampal epigenetic age respect to controls, and the observed changes in DNA methylation partially recapitulated those observed in hippocampi from people with DS. Collectively, our results support the use of the Ts65Dn model to decipher the molecular mechanisms underlying the progeroid DS phenotypes.
Open AccessIncreased hippocampal epigenetic age in the Ts65Dn Mouse Model of Down Syndrome
Down syndrome (DS) is a segmental progeroid genetic disorder associated to multi-systemic precocious ageing phenotypes, which are particularly evident at the immune and nervous systems. Accordingly, people with DS show an increased biological age as measured by epigenetic clocks. Ts65Dn trisomic mouse, which harbors extra-numerary copies of Hsa21-syntenic regions, was shown to recapitulate several progeroid features of DS, but no biomarkers of age have been applied to it so far. Here we used a mouse specific epigenetic clock to measure epigenetic age of hippocampi from Ts65Dn and euploid mice at 20 weeks. Ts65Dn mice showed an increased hippocampal epigenetic age respect to controls, and the observed changes in DNA methylation partially recapitulated those observed in hippocampi from people with DS. Collectively, our results support the use of the Ts65Dn model to decipher the molecular mechanisms underlying the progeroid DS phenotypes.
- Open Access
- 14 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5552
Cardiac Functional and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder
CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a severe neurodevelopmental disease that mostly affects girls, who are heterozygous for mutations in the X-linked CDKL5 gene. Mutations in the CDKL5 gene lead to a lack of CDKL5 protein expression or function and cause numerous clinical features, including early-onset seizures, marked hypotonia, autistic features, gastrointestinal problems, and severe neurodevelopmental impairment. Mouse models of CDD recapitulate several aspects of CDD symptomology, including cognitive impairments, motor deficits, and autistic-like features, and have been useful to dissect the role of CDKL5 in brain development and function. However, our current knowledge of the function of CDKL5 in other organs/tissues besides the brain is still quite limited, reducing the possibility of broad-spectrum interventions. Here, for the first time, we report the presence of cardiac function/structure alterations in heterozygous Cdkl5 +/− female mice. We found a prolonged QT interval (corrected for the heart rate, QTc) and increased heart rate in Cdkl5 +/− mice. These changes correlate with a marked decrease in parasympathetic activity to the heart and in the expression of the Scn5a and Hcn4 voltage-gated channels. Interestingly, Cdkl5 +/− hearts showed increased fibrosis, altered gap junction organization and connexin-43 expression, mitochondrial dysfunction, and increased ROS production. Together, these findings not only contribute to our understanding of the role of CDKL5 in heart structure/function but also document a novel preclinical phenotype for future therapeutic investigation.
- 14 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (6) , 5552
Open AccessCardiac Functional and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder
CDKL5 (cyclin-dependent kinase-like 5) deficiency disorder (CDD) is a severe neurodevelopmental disease that mostly affects girls, who are heterozygous for mutations in the X-linked CDKL5 gene. Mutations in the CDKL5 gene lead to a lack of CDKL5 protein expression or function and cause numerous clinical features, including early-onset seizures, marked hypotonia, autistic features, gastrointestinal problems, and severe neurodevelopmental impairment. Mouse models of CDD recapitulate several aspects of CDD symptomology, including cognitive impairments, motor deficits, and autistic-like features, and have been useful to dissect the role of CDKL5 in brain development and function. However, our current knowledge of the function of CDKL5 in other organs/tissues besides the brain is still quite limited, reducing the possibility of broad-spectrum interventions. Here, for the first time, we report the presence of cardiac function/structure alterations in heterozygous Cdkl5 +/− female mice. We found a prolonged QT interval (corrected for the heart rate, QTc) and increased heart rate in Cdkl5 +/− mice. These changes correlate with a marked decrease in parasympathetic activity to the heart and in the expression of the Scn5a and Hcn4 voltage-gated channels. Interestingly, Cdkl5 +/− hearts showed increased fibrosis, altered gap junction organization and connexin-43 expression, mitochondrial dysfunction, and increased ROS production. Together, these findings not only contribute to our understanding of the role of CDKL5 in heart structure/function but also document a novel preclinical phenotype for future therapeutic investigation.
- Open Access
- 15 September 2022
- Published by Elsevier in Neurotherapeutics
- Vol. 19 (6) , 1886-1904
Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder
- 15 September 2022
- Published by Elsevier in Neurotherapeutics
- Vol. 19 (6) , 1886-1904
Open AccessExpression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder
- Open Access
Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice
Background: Anti-IgLON5 disease is a rare late-onset neurological disease associated with autoantibodies against IgLON5, neuronal accumulation of phosphorylated Tau protein (p-Tau), and sleep, respiratory, and motor alterations. Purpose: We performed a pilot study of whether the neuropathological and clinical features of anti-IgLON5 disease may be recapitulated in mice with chronic intracerebroventricular infusion of human anti-IgLON5 disease IgG (Pt-IgG). Methods: Humanized transgenic hTau mice expressing human Tau protein and wild-type (WT) control mice were infused intracerebroventricularly with Pt-IgG or with antibodies from a control subject for 14 days. The sleep, respiratory, and motor phenotype was evaluated at the end of the antibody infusion and at least 30 days thereafter, followed by immunohistochemical assessment of p-Tau deposition. Results: In female hTau and WT mice infused with Pt-IgG, we found reproducible trends of diffuse neuronal cytoplasmic p-Tau deposits in the brainstem and hippocampus, increased ventilatory period during sleep, and decreased inter-lick interval during wakefulness. These findings were not replicated on male hTau mice. Conclusion: The results of our pilot study suggest, but do not prove, that chronic ICV infusion of mice with Pt-IgG may elicit neuropathological, respiratory, and motor alterations. These results should be considered as preliminary until replicated in larger studies taking account of potential sex differences in mice.
Open AccessPilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice
Background: Anti-IgLON5 disease is a rare late-onset neurological disease associated with autoantibodies against IgLON5, neuronal accumulation of phosphorylated Tau protein (p-Tau), and sleep, respiratory, and motor alterations. Purpose: We performed a pilot study of whether the neuropathological and clinical features of anti-IgLON5 disease may be recapitulated in mice with chronic intracerebroventricular infusion of human anti-IgLON5 disease IgG (Pt-IgG). Methods: Humanized transgenic hTau mice expressing human Tau protein and wild-type (WT) control mice were infused intracerebroventricularly with Pt-IgG or with antibodies from a control subject for 14 days. The sleep, respiratory, and motor phenotype was evaluated at the end of the antibody infusion and at least 30 days thereafter, followed by immunohistochemical assessment of p-Tau deposition. Results: In female hTau and WT mice infused with Pt-IgG, we found reproducible trends of diffuse neuronal cytoplasmic p-Tau deposits in the brainstem and hippocampus, increased ventilatory period during sleep, and decreased inter-lick interval during wakefulness. These findings were not replicated on male hTau mice. Conclusion: The results of our pilot study suggest, but do not prove, that chronic ICV infusion of mice with Pt-IgG may elicit neuropathological, respiratory, and motor alterations. These results should be considered as preliminary until replicated in larger studies taking account of potential sex differences in mice.
- 12 February 2022
- Published by Elsevier
- p. 266-273
Sleep and the peripheral vascular system
- Open Access
- 13 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
Early-life nicotine or cotinine exposure produces long-lasting sleep alterations and downregulation of hippocampal corticosteroid receptors in adult mice
Early-life exposure to environmental toxins like tobacco can permanently re-program body structure and function. Here, we investigated the long-term effects on mouse adult sleep phenotype exerted by early-life exposure to nicotine or to its principal metabolite, cotinine. Moreover, we investigated whether these effects occurred together with a reprogramming of the activity of the hippocampus, a key structure to coordinate the hormonal stress response. Adult male mice born from dams subjected to nicotine (NIC), cotinine (COT) or vehicle (CTRL) treatment in drinking water were implanted with electrodes for sleep recordings. NIC and COT mice spent significantly more time awake than CTRL mice at the transition between the rest (light) and the activity (dark) period. NIC and COT mice showed hippocampal glucocorticoid receptor (GR) downregulation compared to CTRL mice, and NIC mice also showed hippocampal mineralocorticoid receptor downregulation. Hippocampal GR expression significantly and inversely correlated with the amount of wakefulness at the light-to-dark transition, while no changes in DNA methylation were found. We demonstrated that early-life exposure to nicotine (and cotinine) concomitantly entails long-lasting reprogramming of hippocampal activity and sleep phenotype suggesting that the adult sleep phenotype may be modulated by events that occurred during that critical period of life.
- 13 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-13
Open AccessEarly-life nicotine or cotinine exposure produces long-lasting sleep alterations and downregulation of hippocampal corticosteroid receptors in adult mice
Early-life exposure to environmental toxins like tobacco can permanently re-program body structure and function. Here, we investigated the long-term effects on mouse adult sleep phenotype exerted by early-life exposure to nicotine or to its principal metabolite, cotinine. Moreover, we investigated whether these effects occurred together with a reprogramming of the activity of the hippocampus, a key structure to coordinate the hormonal stress response. Adult male mice born from dams subjected to nicotine (NIC), cotinine (COT) or vehicle (CTRL) treatment in drinking water were implanted with electrodes for sleep recordings. NIC and COT mice spent significantly more time awake than CTRL mice at the transition between the rest (light) and the activity (dark) period. NIC and COT mice showed hippocampal glucocorticoid receptor (GR) downregulation compared to CTRL mice, and NIC mice also showed hippocampal mineralocorticoid receptor downregulation. Hippocampal GR expression significantly and inversely correlated with the amount of wakefulness at the light-to-dark transition, while no changes in DNA methylation were found. We demonstrated that early-life exposure to nicotine (and cotinine) concomitantly entails long-lasting reprogramming of hippocampal activity and sleep phenotype suggesting that the adult sleep phenotype may be modulated by events that occurred during that critical period of life.